Head & Neck
- 61598
- FDG for staging of biopsy-proven newly diagnosed or recurrent head and neck cancer
- 61604
- FDG for evaluation of patients with suspected residual head and neck cancer after definitive treatment
SCC
- 61610
- FDG for evaluation of metastatic SCC of an unknown primary site when cervical lymph nodes are involved
Lung
- 61523
- FDG for solitary pulmonary nodule deemed unsuitable for transthoracic biopsy or where biopsy has failed
- 61529
- FDG for staging confirmed non-small cell lung cancer prior to planned curative surgery or radiotherapy
Breast
- 61524
- FDG for stage III breast carcinoma in patients considered suitable for active therapy
- 61525
- FDG for suspected metastatic or locoregional recurrent breast cancer in patients appropriate for therapy
Brain
- 61538
- FDG for suspected residual or recurrent malignant brain tumour
- 61559
- FDG for refractory epilepsy assessed for potential surgery
- 61560
- FDG for Alzheimer’s diagnosis when specialist evaluation is equivocal. Excluded if PET/SPECT brain has been done in past 12 months (maximum 3 scans per lifetime)
Lymphoma
- 61620
- FDG for initial staging of newly diagnosed or untreated Hodgkin’s or non-Hodgkin’s lymphoma
- 61622
- FDG for assessing response during or within 3 months of completing first-line therapy in lymphoma
- 61628
- FDG for restaging after confirmed recurrence of lymphoma
- 61632
- FDG for assessing response to second-line chemotherapy when stem cell transplant is being considered
FDG Avid Cancers
- 61612
- FDG for staging of FDG-avid cancers; limit one per diagnosis
- 61614
- FDG for evaluating suspected residual, metastatic or recurrent FDG-avid cancers
Sarcoma
- 61640
- FDG for staging potentially curable biopsy-proven bone or soft tissue sarcoma (excluding GIST)
- 61646
- FDG for suspected residual or recurrent bone/soft tissue sarcoma (excluding GIST)
Gynaecological
- 61571
- FDG for primary staging of uterine cervix carcinoma at FIGO IB2 or higher, prior to radical radiation therapy or combined modality therapy
- 61565
- FDG for suspected residual, metastatic or recurrent ovarian carcinoma
- 61575
- FDG for staging confirmed local recurrence of uterine cervix carcinoma
Gastrointestinal
- 61541
- FDG for suspected residual, metastatic or recurrent colorectal carcinoma post initial therapy
- 61577
- FDG for staging oesophageal or gastro-oesophageal junction carcinoma
Neuroendocrine
- 61647
- Ga-DOTA peptide PET when GEP-NET is suspected biochemically with negative/equivocal conventional imaging, or to exclude additional disease sites in surgically amenable tumours
Melanoma
- 61553
- FDG for suspected metastatic or recurrent malignant melanoma after initial therapy
Prostate & Lutetium-PSMA
- 61563
- Initial staging in previously untreated intermediate/high-risk prostate adenocarcinoma (e.g. PSA 10–20, Gleason ≥7, stage ≥T2b), once per lifetime
- 61564
- Restaging recurrent prostate adenocarcinoma after prior locoregional therapy with PSA rise ≥2 ng/mL above nadir or failure to fall to undetectable levels; or rising PSA serum after a radical prostatectomy; limited to 2 per lifetime
- 61528
- Assess eligibility for Lutetium-177 PSMA therapy in metastatic castrate-resistant prostate cancer after disease progression on at least one taxane chemotherapy and one androgen receptor signalling inhibitor
- 16050
- Initial 177Lu PSMA therapy, applicable once per cycle, up to a maximum of 2 cycles in the initial treatment phase
- 16055
- Continued 177Lu PSMA therapy, applicable once per cycle, up to a maximum of 4 cycles in the initial treatment phase